NEW YORK – Janssen said on Monday it is seeking approval from the European Medicines Agency for amivantamab as a treatment for metastatic non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
NEW YORK – Janssen said on Monday it is seeking approval from the European Medicines Agency for amivantamab as a treatment for metastatic non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.